LungÕ 2026: Global Experts Examine the Changing Landscape of Lung Cancer Care
After a Decade Without a New Option, FDA Approves Amivantamab for Head and Neck Cancer
Solomon Moshkevich Named CEO of Natera
SIOG 2026: 15 Posts Not to Miss from the Annual Conference in Valencia
Prostate Cancer Radiotherapy: HYPO-RT-PC Study Reveals Significant Gaps Between Patient and Clinician Symptom Reporting
Can Laser Hair Removal Cause Cancer? What Science Says
Timothy Rebbeck: Science Gains a Stronger Voice in the U.S. Congress
OncoDaily GI is the dedicated GI cancer platform of OncoDaily, focused on the rapidly evolving field of gastrointestinal oncology. It covers the full spectrum of GI malignancies, including colorectal, anal canal, gastric, gastroesophageal junction (GEJ), esophageal, small bowel, pancreatic, hepatocellular, and biliary tract cancers. Through OncoDaily GI, readers can follow the latest clinical trial developments, ongoing research, FDA and EMA approvals, guideline updates, emerging therapies, advances in biomarkers and precision oncology, major conference findings, and interviews with leading experts in the field.
